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Summary
Background: Opportunistic infections (OIs) influence the morbidity and mortality due to HIV
infections. Data from India on the incidence of OIs among HIV-infected individuals by stages of
immunodeficiency are scarce.
Methods: Between September 2002 and November 2004, HIV-infected individuals were enrolled
in a prospective study in Pune. They were clinically and immunologically evaluated quarterly.
Incidence rates of specific OIs were calculated.
Results: Median CD4 counts in HIV-infected male and female patients at baseline were 197/mm3
and 413/mm3, respectively. Tuberculosis was the most common OI with an incidence of 15.4 (95%
CI 12.2—19.2) per 100 person-years, followed by oral candidiasis 11.3 (95% CI 8.6—14.5), herpes
zoster 10.1 (95% CI 7.6—13.1), and cryptococcal meningitis 1.7 (95% CI 0.8—3.1) per 100 person-
years. Patients with baseline CD4 counts of <200/mm3 were six times more likely to develop OIs
compared to those with CD4 counts of >350/mm3 ( p < 0.001).
Conclusions: The high incidence of commonly reported OIs in Indian HIV-infected individuals
highlights the need for early screening and also the need to increase awareness in healthcare
providers, in order to improve decisions regarding prophylaxis for prevention and appropriate
therapeutic intervention. Emphasis needs to be given to the early diagnosis and management of
tuberculosis in HIV-infected individuals.
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It has recently been estimated that 2.5 million individuals are
living with HIV infection in India.1 With an HIV epidemic
history in the country of more than two decades duration,2
an increase in the number of persons at the advanced stage of
disease presenting with medical complications is expected,
and this is likely to pose a challenge to the healthcare
delivery system. Opportunistic infections (OIs), leading to
significant morbidity and mortality might grossly affect the
health and quality of life of people infected with HIV.3 There
is global evidence that the overall incidence of opportunistic
diseases increases with the degree of immunosuppression
resulting from HIV disease progression.4,5
The primary medical care for HIV/AIDS in India mainly
consists of symptomatic supportive treatment, chemopro-
phylaxis, and management of OIs. The Government of India
initiated a free antiretroviral therapy (ART) roll-out program
in 2004, and around 39 000 patients had been placed on ART
by the end of March 2006.6 Even if initiation of ART results in
the suppression of OIs,7 issues of non-adherence, ART drug
resistance, and treatment failure might not be able to totally
prevent or avert OIs among the HIV-infected. Also, in a
resource-limited setting like India, every individual who is
eligible to receive ARTcannot be covered in the Government-
sponsored ART program, and those who are not covered will
not necessarily be able to afford to buy the drugs on their
own.
Many studies on HIV prevalent cohorts have reported and
described the spectrum of OIs worldwide, including in
India.8—10 Tuberculosis is the most commonly reported OI
among HIV-infected individuals in India.3,11—13 Other com-
monly reported OIs include oral candidiasis, herpes zoster,
cryptococcal meningitis, cerebral toxoplasmosis, and cyto-
megalovirus retinitis.3,8,14—16
Although, data on the ‘prevalence’ of various OIs from
HIV-infected individuals are available, data on the ‘inci-
dence’ of OIs in India are scarce. A natural history study
from Mumbai among HIV-infected individuals documented
the annual incidence of active clinical tuberculosis as 5.7/
100 person-years, and emphasized strategies to prevent the
occurrence of tuberculosis among HIV-infected patients.13 A
retrospective analysis from southern India reported the pre-
valence and survival patterns in different OIs.17 However,
incidence rates of OIs from a prospective study of HIV-
infected individuals at various levels of immunosuppression
have not been reported from India. Such estimates would be
useful to guide healthcare workers in the institution of
appropriate intervention strategies for the prevention of
specific OIs, and also in the decision to initiate ART. In a
prospective cohort study in Pune, India, we estimated the
incidence of commonly occurring OIs, including tuberculosis,
among HIV-infected individuals at various levels of immuno-
suppression.
Materials and methods
In collaboration with the Johns Hopkins University, Balti-
more, USA, the National AIDS Research Institute, Pune con-
ducted a prospective cohort study entitled ‘‘HIV incidence
and participant retention’’ as part of the HIV Prevention TrialNetwork (HPTN) funded by the National Institutes of Health
(NIH), USA. The study was carried out in Pune, a city located
in the high HIV prevalence state of Maharashtra in India. The
study was initiated in September 2002, enrolling HIV sero-
discordant couples, with the objectives of determining the
incidence of HIV infection in the uninfected spouses of HIV-
infected persons and the retention of the enrolled couples in
the cohort at the end of one year. Enrollment into the study
was continued until November 2004. Although originally
designed as a one-year follow-up study, the follow-up was
extended until August 2005 to accumulate more person-years
of follow-up for the determination of HIV incidence. In this
paper, we present the findings from the HIV-infected partners
who were enrolled and followed as a part of the HIV dis-
cordant couples cohort.
Patients and clinic-based procedures
The study was approved by the Scientific Advisory Committee
and Ethics Committee of the National AIDS Research Insti-
tute. Demographic and clinical data were captured at each
follow-up visit; HIV-infected individuals were called for 3-
monthly follow-up visits. The clinical procedures in the study
consisted of pre-test and post-test counseling, informed
consents, and collection of demographic and clinical infor-
mation on structured proformas. HIV-infected participants
weremonitored for their CD4 count and viral load estimations
every 3 and 6months, respectively. Participants were advised
to report to the study physicians for any illnesses. They were
clinically evaluated by study physicians during all follow-up
visits and also during unscheduled interim visits whenever
required. The study participants requiring in-patient care
were admitted to two pre-identified local hospitals and were
jointly managed by the study and hospital physicians.
Clinical management
Patients were categorized into stages I, II, III, and IV based on
World Health Organization (WHO) clinical staging criteria
after their study enrollment.18 The following case definitions
were used for common OIs based on clinical presentation
and/or reports of laboratory investigations as part of the
locally available standard of care: (1) tuberculosis: clinical
presentation suggestive of pulmonary or extrapulmonary
tuberculosis along with supportive evidence (chest X-ray,
Mantoux test, sputum examination for acid-fast bacilli, fine
needle aspiration cytology and/or biopsy for tubercular lym-
phadenitis, ultrasonography of the abdomen for evidence of
lymph nodes, or cerebrospinal fluid (CSF) examination for
tubercular meningitis); (2) oral candidiasis: clinical evidence
supported by clinical response to appropriate therapy; (3)
herpes zoster: clinical evidence of prototypic skin eruptions
with pain along with typical dermatological distribution; (4)
cryptococcal meningitis: clinical evidence of meningitis with
demonstration of cryptococci in the CSF detected by India ink
preparation.
All patients were provided with the appropriate locally
available standard clinical care for their illnesses. Trimetho-
prim—sulfamethoxazole prophylaxis (once daily, orally) was
initiated for the prevention of Pneumocystis jiroveci pneu-
monia when CD4 counts fell below 200/mm3. Patients were
Incidence of OIs in the HIV-infected, Pune, India e3advised to commence ART as per national guidelines,19 and
this was initiated in patients who were willing and could
afford it, following adherence counseling. OIs were diag-
nosed on the basis of clinical evaluation supported by appro-
priate laboratory investigations.
Statistical analysis
Baseline characteristics of HIV-infected individuals were
compared by gender employing appropriate statistical tests.
Patients who did not present with any specific OI at study
enrollment were considered at risk of developing an OI from
their date of entry into the study until their last date of visit,
or the date of development of such an event. Patients who
presented to the clinic with pre-existing conditions were
excluded from the incidence estimation.
We initially calculated incidence rates for any OI (tubercu-
losis, herpes zoster, oral candidiasis, cryptococcal meningitis,
cytomegalovirus retinitis, toxoplasmosis, cryptosporidium
diarrhea, etc.) experienced by the participants during the
follow-up visits, but commonly reported OIs from our popula-
tion (n = 10 ormore) were considered for subsequent in-depth
analysis. Only the first OIwas considered for this analysis, even
if the patient had more than one OI subsequently. The Cox
proportional hazards model20 was used to assess the relation-
ship between baseline characteristics and progression to any
OI, adjusted for theCD4 count. The relative risk (RR) estimates
reflect the relative hazard estimates from the model.
We also carried out a detailed analysis for four of the
commonly diagnosed conditions: tuberculosis (pulmonary
and extrapulmonary), oral candidiasis, herpes zoster, and
cryptococcal meningitis. In this analysis, we used the time
from study entry to development of that specific OI for
calculation of person-years for incidence estimation and
did not consider any other OI that might have occurred during
this interval. Incidence rates were estimated by age, gender,
CD4 counts, and antiretroviral status at baseline, and 95%
confidence intervals were calculated.
Kaplan—Meier survival analysis was performed to deter-
mine survival or disease-free time from common OIs among
the study participants by different categories of CD4 counts.
Log rank statistics were used to test the equality of survival
distributions. Results were considered statistically significant
with a two-sided p value of <0.05. Data analysis was carried
out using SPSS (version 14.0, SPSS Inc., USA).
Results
As a part of the prospective cohort study, 457 consenting HIV-
infected individuals and their spouses were enrolled and
followed. The median duration of follow-up was 15 months,
with the accumulation of 625 person-years of follow-up. The
male:female ratio in the enrolled study participants was 6:1.
The median age of the 393 HIV-infected males was sig-
nificantly higher than that of the 64 HIV-infected females (34
years vs. 28 years; p < 0.001). The median CD4 count in HIV-
infected male patients was significantly lower than in female
patients: 197/mm3 (IQR 96—338) vs. 413/mm3 (IQR 249—
496), respectively ( p < 0.001). Males were nearly three
times more likely to be at an advanced stage of immunosup-
pression (characterized by CD4 counts of <200/mm3) ascompared to females (51% and 19%, respectively). The med-
ian viral load in males was 109 622 RNA copies/ml (IQR 25
106—261 416) and was significantly higher than that in
females (20 614 RNA copies/ml (IQR 2222—118 384);
p < 0.001). At the time of study entry, 53%, 8%, 21%, and
18% of individuals were at WHO stages I, II, III, and IV of the
disease, respectively. Males weremore likely to be at stages II
and III of HIV disease ( p < 0.001). A history of tuberculosis,
oral candidiasis, and herpes zoster in the past was found in
22.5%, 8%, and 27.1% individuals, respectively (data not
shown). Nine percent of male patients and 5% of female
patients were already on ART at the study initiation
( p = 0.48).
Sixty-seven HIV-infected individuals (65 males and two
females) had at least one OI at the study entry visit and were
not considered for the subsequent incidence analysis. Table 1
summarizes the incidence rate and relative risk of developing
any OI by baseline characteristics for the remaining 390 study
participants. The overall incidence of OIs was 35.7 per 100
person-years of follow-up (95% CI 30.1—41.9), with a total of
147 OI events reported by the respondents. The incidence of
OIs was higher in the older age groups, in males, and among
patients with low CD4 counts and not on antiretroviral treat-
ment. Although males had a significantly higher risk of devel-
oping OIs than females (RR of 1.0 vs. 0.5 (95% CI 0.3—0.8;
p = 0.008)), the difference was not statistically significant
after adjusting for CD4 counts ( p = 0.51). Patients with a
baseline CD4 count <200/mm3 were almost six times more
likely to develop OIs compared to those with CD4 counts of
>350/mm3 (95% CI 3.6—9.9; p < 0.001). These findings
remained unchanged even after adjusting for age, gender,
and ART at baseline. The incidence of any OI was lower in
patients exposed to highly active antiretroviral therapy
(HAART) (23.9, 95% CI 12.3—41.7) as compared to the
HAART-naı¨ve population (37.3, 95% CI 31.3—44.2). However,
this difference was not statistically significant.
Incidence rates of four commonly reported OIs among HIV-
infected individuals by gender are summarized in Table 2.
The overall incidence of tuberculosis was 15.4 per 100 per-
son-years of follow-up (95% CI 12.2—19.2). The incidence of
extrapulmonary tuberculosis was higher (7.9 per 100 person-
years) than pulmonary tuberculosis (6.9 per 100 person-
years), resulting in the reporting of 45 and 39 cases of
extrapulmonary and pulmonary tuberculosis, respectively,
among the study participants during the follow-up. Four
patients developed pulmonary as well as extrapulmonary
tuberculosis during the follow-up period.
The incidence rates of herpes zoster and oral candidiasis
were above 10% per year in all the patients and also in males
(10.5% for herpes zoster and 11.7% for oral candidiasis, per
year). In females, the incidence rates of herpes zoster and
oral candidiasis were 7.6 and 8.8 per 100 person-years,
respectively. The incidence of cryptococcal meningitis and
other conditions was comparatively low (range 1.2 to 3.7 per
100 person-years in men and women). The incidence rates
were lower in females as compared to males for all of the
commonly observed OIs.
Median CD4 counts around the time of developing tuber-
culosis, herpes zoster, oral candidiasis, and cryptococcal
meningitis were 114.0/mm3 (IQR 58.0—195.0), 207/mm3
(IQR 146—293), 113/mm3 (IQR 39—203), and 71/mm3 (IQR
39—118), respectively. Themedian CD4 count among patients
Table 1 Incidence and relative risk of any opportunistic infections (OIs) by baseline CD4 counts, demographic characteristics, and
antiretroviral treatment status
Characteristic No. OI a Rate /100 person-years (95% CI) Relative risk
Unadjusted p Adjustedb p
All 390 147 35.7 (30.1—41.9)
Age
45 30 12 42.3 (21.9—73.9) 2.8 (0.8—10.0) 0.17 1.3 (0.4—4.7) 0.71
35—45 139 59 43.1 (32.8—55.5) 3.0 (0.9—9.5) 0.07 1.3 (0.4—4.3) 0.62
25—35 202 73 32.2 (25.2—40.4) 2.2 (0.7—7.1) 0.10 1.2 (0.4—4.0) 0.68
<25 19 3 14.7 (2.9—42.8) 1 1
Total 390 147
Gender
Female 62 13 17.9 (9.5—30.7) 0.5 (0.3—0.8) 0.008 0.8 (0.5—1.5) 0.51
Male 328 134 39.4 (33.0—46.7) 1 1
Total 390 147
CD4 count/mm3
<200 164 91 69.6 (56.1—85.4) 6.0 (3.6—9.9) <0.001
200—350 104 37 32.5 (22.9—44.8) 2.9 (1.6—5.1) <0.001
350 121 18 10.7 (6.4—17.0) 1
Total 389c 146
Antiretroviral treatment
No 353 135 37.3 (31.3—44.2) 1.5 (0.8—2.7) 0.19 1.2 (0.7—2.2) 0.49
Yes 37 12 23.9 (12.3—41.7) 1 1
Total 390 147
a Opportunistic infection (OI): any incident opportunistic infection diagnosed in the HIV-infected individual during follow-up.
b Adjusted relative risk for baseline CD4 count.
c Missing data: data were missing for one individual.
e4 M. Ghate et al.who developed pulmonary tuberculosis was 142/mm3 (IQR
44—244) and the median CD4 count among those who devel-
oped extrapulmonary tuberculosis was 94/mm3 (IQR 70—
143). This difference was not statistically significant.
Figure 1 shows the incidence of various OIs among study
participants stratified by CD4 counts. It was observed that the
patients at an advanced stage of immunosuppression had aFigure 1 Incidence of opportunistic infections (OIs) by base-
line CD4 counts in HIV-infected individuals in Pune, India.very high chance of developing an OI. A classical stepladder
pattern was observed, indicating increasing incidence rates
of OIs with falls in CD4 counts. The incidence of pulmonary
tuberculosis, extrapulmonary tuberculosis, oral candidiasis,
herpes zoster, and cryptococcal meningitis increased many-
fold with falling CD4 counts. The risk of developing tubercu-
losis and oral candidiasis was more than 10 times greater at
CD4 counts of <200/mm3 compared to at CD4 counts of
>350/mm3. Even among patients who had a CD4 count range
of 200—350/mm3 at baseline, the incidence rates of tuber-
culosis and herpes zoster were above 11 per 100 person-
years.
Kaplan—Meier analysis for common OIs in different cate-
gories of CD4 counts showed that there was an increased risk
of developing OIs almost immediately after the CD4 count
started falling below 200/mm3 (Figure 2). The period of
acquisition of common OIs was longer at higher CD4 counts
except for herpes zoster, where the risk of getting the disease
was high even at higher CD4 counts.
Discussion
Many research studies have described the types and rates of
OIs in HIV-infected individuals globally.21,22 It has also been
reported that the incidence of OIs has decreased in devel-
oped countries due to the availability of ART.23,24 However, in
India in the present phase of transition of the epidemic from
HIV infection to AIDS, a rise in the burden of OIs is antici-
pated.
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Incidence of OIs in the HIV-infected, Pune, India e5The HIV epidemic in India is geographically diverse and
there are regional differences, not only in the incidence and
prevalence of HIV infection, but also in the burden of back-
ground communicable diseases. Facilities and access to
healthcare in rural areas are limited. While preparing appro-
priate strategies for the effective management of AIDS
patients, significant effort and investment will have to be
made to build infrastructure, diagnostic facilities, and clin-
ical expertise to manage OIs. If the public health managers
are provided with accurate estimates of the existing burden
and the rate of occurrence of OIs among HIV-infected indi-
viduals, they will be able to plan and implement appropriate
management strategies and interventions. The highlight of
our data is that we are reporting the incidence rates of four
commonly observed OIs at various levels of immunosuppres-
sion in HIV-infected patients enrolled in a prospective study
in Pune.
The strengths of this study include the recruitment of a
cross-section of HIV-infected individuals and an excellent
retention up to one year. We observed that the male:female
ratio of HIV-infected index cases in the HIV discordant couple
setting was 6:1. This is higher than that reported elsewhere in
India17 and probably reflects the selective intake of couples
in our study. The HIV epidemic in Indian women is younger
than that in men, and this is why men are more likely to enter
the study at an advanced stage of the disease than women.
Higher viral loads and lower CD4 counts among male study
participants indicate that they are at a more advanced stage
of HIV disease. This also explains why the incidence of OIs was
lower in women as compared to men.
The overall incidence of OIs in our study population was
35.7/100 person-years of follow-up. The chances of devel-
oping OIs increased with decreasing CD4 counts, and inci-
dence rates of OIs were six times higher in patients with CD4
counts below 200/mm3 as compared to others. These findings
are consistent with observations from other developed and
developing countries.5 A study from Brazil reported an inci-
dence of 51% OIs per year in patients with CD4 counts below
100/mm3 who were either on monotherapy or dual therapy
antiretroviral regimens.25 In a study in southern India, the
incidence of OIs before initiation of ARTwas up to 10 per 100
person-years of follow-up.26 This is low compared to our
study, and may be due to the difference in the profile of
the study population, study design, and differential follow-
up rates.
The high incidence of OIs in our study was expected, as
nearly half of the study participants entered the study at an
advanced stage of immunosuppression and the majority were
ART-naı¨ve. The patients who were on ART prior to study entry
had a lower chance of developing OIs. This finding is similar to
reports from other developed and developing countries,
which have shown declines in the incidence of OIs as well
as mortality in HIV-infected patients after the initiation of
ART.23,24 However, the observation that the incidence of OIs
in those on HAARTand in the HAART-naı¨ve in our study was not
statistically different could be attributed to the small sample
size of patients on HAART at baseline and a lack of informa-
tion on drug compliance and adherence at the intermediate
point of study participant evaluation. With the availability of
free antiretroviral drugs provided by the Government of
India, the incidence of OIs is likely to reduce, but the
sustainability of ART, the emergence of antiretroviral resis-
Figure 2 Kaplan—Meier survival curves for common opportunistic infections (OIs) stratified by baseline CD4 counts in HIV-infected
individuals in Pune, India.
e6 M. Ghate et al.tance, themanagement of treatment failures, and the lack of
compliance to ARTare likely to be challenges that will have to
be dealt with in the future.
The overall incidence of tuberculosis in our study popula-
tion was much higher than that reported in Western coun-
tries.5,27 It was also higher than that reported from South
Africa in AIDS patients not at an advanced clinical stage of
disease.28 Though tuberculosis is the most commonly
reported HIV-related OI in India,29 our study is the first
prospective study to demonstrate a marked increase in
tuberculosis incidence with advanced degree of immunosup-
pression.
A natural history study from western India (Mumbai)
reported the incidence of pulmonary tuberculosis to be 5.7
per 100 person-years of follow-up.13 Managing the dual HIV—
tuberculosis epidemic is a major public health challenge. In
our study, the median CD4 count at the development of
pulmonary tuberculosis was 142/mm3, which is higher than
that reported in a natural history study in southern India
(111/mm3).17 We have also reported a high incidence of
extrapulmonary tuberculosis. A study in northern India stated
that both pulmonary and extrapulmonary tuberculosis had
low positive predictive values (PPV; 51% and 42%, respec-
tively) for CD4 levels of <200/mm3 as compared to dissemi-
nated tuberculosis including extrapulmonary tuberculosis
(75%) in AIDS patients.30 A study in Nigeria reported the
prevalence of extrapulmonary tuberculosis to be 13.7%,
higher than in our population, with a mean CD4 count of
107/mm3, which was similar to our finding.4 A study from the
Netherlands reported a rise in prevalence of extrapulmonary
tuberculosis from 24.5% in 1993 to 51.8% in 2000 among HIV-
infected individuals, but this rise was mainly attributed to
the increase in AIDS patients of foreign descent.31
The diagnosis and management of tuberculosis, espe-
cially, extrapulmonary tuberculosis, is likely to pose uniquechallenges for medical practitioners from the diagnostic
viewpoint, particularly in resource-limited settings.
Although early diagnosis of extrapulmonary tuberculosis
can be a challenge, if accomplished it can significantly
reduce associated morbidity and mortality. The issue of
prophylaxis against tuberculosis in HIV-infected individuals,
especially using a potent drug like isoniazid, is debatable.
However, it is certainly important that studies be undertaken
to evaluate various drugs that can be used as prophylactic
agents against tuberculosis in HIV-infected persons in settings
like India, where there is a high disease burden of tubercu-
losis. Early prediction, correct diagnosis, and appropriate
intervention for tuberculosis are likely to result in significant
public health benefits. Another study from the city of Pune
has also stressed the important role of private medical
practitioners in treating HIV and tuberculosis co-infected
patients.32
Oral candidiasis is a commonly described OI globally33 and
has been reported as a marker of immunosuppression.34,35
The high incidence of oral candidiasis, especially at low CD4
counts, necessitates the introduction of appropriate inter-
vention for the same.3,8,34,35 The median CD4 counts at the
time of diagnosis of oral candidiasis in our study were lower
than those determined elsewhere,36 but in India this condi-
tion is shown to have an association with low CD4 counts.34,37
Oral candidiasis is one of the clinical markers of immuno-
suppression, and antiretroviral therapy should be initiated in
patients with persistent oral candidiasis if facilities for per-
forming CD4 counts are not available. A study has shown that
ART is highly effective in decreasing oral candidiasis in
association with a rise in CD4 counts.38
Herpes zoster, a commonly reported skin condition,8,39
was found in our study population, even at higher CD4 counts
compared to the other common OIs, and the median CD4
count at the time of diagnosis was observed to be 207/mm3. A
Incidence of OIs in the HIV-infected, Pune, India e7higher incidence of herpes zoster (17.21 per 100 person-
years) was reported in Taiwan in the pre-HAART era.40 The
incidence of herpes zoster was lower than that reported in
developed countries,41 but similar to that reported in
another Indian study (11.8%).42 The sequelae and chronic
complications of this condition need to be studied, and the
role of herpes vaccine in HIV-infected individuals needs to be
evaluated in India.
Among the different infections affecting the central ner-
vous system, cryptococcal meningitis is the most common
HIV-associated complication both in developed and develop-
ing countries,43,44 contributing significantly to increased
morbidity and mortality. This is the most common type of
meningitis reported in important neurological studies in
India.16,45 Cryptococcal meningitis, an AIDS-defining illness,
usually appears when CD4 counts are below 100/mm3 and is
associated with an increased risk of death. Clinicians should
carefully investigate those patients with very low CD4 counts
presenting with symptoms suggestive of meningitis. Early
diagnosis and effective treatment may considerably reduce
the morbidity and mortality associated with this condition.
There are certain limitations to our study: (1) the sample
size was small, especially for women, and this did not allow
elaborate gender-specific analysis; (2) the follow-up was
short-term; (3) we were not able to capture the details of
ART drug regimens and adherence, and it is possible that
patients were taking treatment irregularly; (4) the diagnoses
of herpes zoster and oral candidiasis were mainly based on
clinical examination and response to therapy; (5) all the
pulmonary tuberculosis cases were not confirmed by sputum
culture; and (6) data on Pneumocystis jiroveci pneumonia
were not included as we could not perform specialized
diagnostic techniques of confirmation for this clinical condi-
tion. However, we feel that for the resource-limited setting,
we have used the best available diagnostic algorithms for OIs,
as would reflect the ‘real life situation’.
This study provides important information about the risks
of commonly reported OIs at lower CD4 counts. These results
highlight the need for early screening and also the need to
increase awareness in healthcare providers in order to
improve decisions regarding prophylaxis for prevention and
appropriate therapeutic interventions. This will reduce the
morbidity and improve the quality of life of HIV-infected
individuals. As the free ART roll-out program is extended to
many states in India, many long-term studies will have to be
undertaken to assess the effects of this program on the
incidence of various OIs. Our study will also help program
managers to plan appropriate strategies for the investigation
and treatment of common OIs as a part of the management
package for HIV-infected populations.Acknowledgements
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